Actualités

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.

Merck (MRK) is back in focus after a run of product and earnings headlines. Fresh approvals and label expansion efforts for KEYTRUDA and ENFLONSIA now sit alongside a raised 2026 revenue outlook and recent acquisition charges. See our latest analysis for Merck. Merck’s share price has moved to US$128.37 after a strong run, with a 90 day share price return of 15.25% and a 1 year total shareholder return of 65.06%, suggesting momentum has been building as approvals, trial readouts and raised...

By Anna Szymanski August 7 (Reuters) - Your weekly market recap, with reading, watching and listening recommendations from the ROI team From the Editor Tech earnings hogged the spotlight this week, as

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

The company says it expects to have mFlusiva ready for the upcoming 2026-2027 flu season, which runs from roughly October to May.

Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year

Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.

Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?

Ligand stock bounded out of a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.

Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.

Merck has outperformed the broader market over the past year, and analysts remain optimistic about the stock.

Merck KGaA (ETR:MRK) reported accelerating organic sales and earnings growth in the second quarter of 2026, led by Life Science and Electronics, and raised its full-year outlook for sales, EBITDA pre and earnings per share. Group net sales rose 3.4% year over year to €5.434 billion. Organic sales g

Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Moby summary of Arcus Biosciences, Inc.'s Q2 2026 earnings call

This study miss marks a setback for Gilead’s Trodelvy expansion plans, which include both mono and combination therapy approaches.

Investing.com-- Merck clocked a stronger second-quarter adjusted profit on Tuesday, aided by strong performances in its life science and electronics divisions, with the company also raising its annual profit outlook.

The group pointed to stronger demand in the life-science and electronics markets and resilience in its healthcare operations.

The market is pricing in an unusually high cash-generation yield for one of the world's largest drugmakers, forcing investors to decide if the price reflects a temporary problem or a permanent decline.

A new round of strong earnings reports powered the Dow Jones Industrial Average to a fresh high on Wednesday, underscoring how surging profits are underpinning the stock-market rally. Upbeat reports from Amgen Walt Disney and Merck helped send the blue-chip index 0.5%, or 263 points, higher to 54349. The Dow industrials have now climbed for five straight sessions, notching three straight records and a 5.3% gain in their best such run since the volatile days of the April 2025 tariff panic.

Merck (NYSE:MRK) is approaching a major patent cliff for cancer drug Keytruda from 2028. The company is increasing acquisitions and partnerships to broaden its portfolio beyond oncology. Merck is building pipelines in areas such as hematology, infectious diseases, cardiopulmonary, vaccines, and obesity. For investors watching large pharmaceutical companies, Merck sits at an important turning point. Keytruda has been a central product for years, and the upcoming patent expirations put more...

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the rally has room left to run.

Merck raised its 2026 sales outlook as pipeline gains, new launches and post-KEYTRUDA plans took focus despite acquisition-driven losses.

MSD is currently evaluating tulisokibart in six different indications following the drug’s discontinuation in SSc-ILD.

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

Merck & Co., Inc. (NYSE:MRK) reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield. T

Keytruda made Merck an oncology powerhouse, but as the patent cliff looms, its business development leader outlines what’s next.

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

Moby summary of Merck & Co., Inc.'s Q2 2026 earnings call

Merck raises full-year guidance on robust KEYTRUDA and new product momentum, while navigating acquisition-related EPS impact and pipeline setbacks.